Conditions: B-Cell Neoplasm Estrogen Receptor Negative HER2/Neu Negative Metastatic Renal Cell Cancer Progesterone Receptor Negative Stage III Mesothelioma Stage III Renal Cell Cancer Stage IIIA Breast Cancer Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Stage IV Mesothelioma Stage IV Non-Small Cell Lung Cancer Stage IV Renal Cell Cancer Triple-Negative Breast Carcinoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Detailed description:
OUTLINE:

Patients are evaluated with a PET/CT scan using the radiolabel 18F-FSPG \[18F-(S)-4-(3-fluoropropyl)-L-glutamic acid\] or 18F-FDG (\[18F\]-fluorodeoxyglucose), before and after therapeutic treatment.

PRIMARY OBJECTIVE:

Uptake of the radiolabel 18F-FSPG in patients with biopsy-proven cancer will be evaluated and compared to the uptake of 18F-FDG, before and after therapy (non-specified) in the same group of patients.

SECONDARY OBJECTIVES:

* Compare the agreement of the clinical assessment for cancer status between 18F-FSPG and 18F-FDG.
* Safety and tolerability of 18F-FSPG and 18F-FDG.

Arms:
arm 1: Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.

Interventions: intervention 1: 18F-FSPG intervention 2: 18F-FDG
Intervention descriptions: intervention 1: Administered intravenously (IV) intervention 2: Administered intravenously (IV)

Protocol document: